DEA's Proposed Rules on Controlled Substances Prescribing via Telemedicine and Their Uncertain Impact on the Pharmacy Community
Proposed rules would permit a telehealth provider to prescribe only up to a 30-day supply of a Schedule III-V non-narcotic controlled substance or buprenorphine through telehealth without the patient first being evaluated in person by a provider.
White House District Of Columbia United States Walmart Inc American Telemedicine Association National Association Of Boards Pharmacy
Source: pharmacytimes.com